Document Detail


Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
MedLine Citation:
PMID:  8705214     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To develop a method of determining the characteristics of epirubicin resistance and to study the reversal of such resistance in the intravesical treatment of superficial bladder cancer, using sensitive and resistant derivatives of a bladder cancer cell line in vitro. MATERIALS AND METHODS: Epirubicin fluorescence and flow cytometry were used to measure the intracellular levels of epirubicin in both sensitive and resistant live cultured bladder tumour cells, with and without different doses of the resistance-reversing agent verapamil. RESULTS: There was a reliable, highly significant and consistent difference in intracellular epirubicin concentration between the resistant and sensitive bladder tumour cells. In addition, it was possible to substantially reverse the features of resistant cell subline with additional verapamil. CONCLUSION: Application of this assay to clinical specimens should allow better targeting of epirubicin intravesical chemotherapy and avoid the premature termination of such treatment in patients whose tumours remain sensitive to this agent. Furthermore, the addition of verapamil to intravesical epirubicin may permit effective treatment of those patients whose tumours have inherent or acquired resistance to epirubicin.
Authors:
P M Duffy; M C Hayes; A Cooper; C J Smart
Related Documents :
11564034 - Immunohistochemical analysis of ki-67, p21waf1/cip1 and apoptosis in marker lesions fro...
11820414 - Routine follow-up cystoscopy in detection of recurrence in patients being monitored for...
12814674 - Significance of random bladder biopsies in superficial bladder cancer.
11057774 - Adjuvant chemotherapy for non-organ confined disease after radical cystectomy.
10941154 - High-dose intra-arterial cisplatin and concurrent hyperfractionated radiation therapy i...
21378204 - Phase ii study of nedaplatin and docetaxel in patients with advanced squamous cell carc...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of urology     Volume:  77     ISSN:  0007-1331     ISO Abbreviation:  Br J Urol     Publication Date:  1996 Jun 
Date Detail:
Created Date:  1996-09-11     Completed Date:  1996-09-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  15740090R     Medline TA:  Br J Urol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  819-23     Citation Subset:  IM    
Affiliation:
Department of Urology, Southampton University Hospitals NHS Trust, Southampton, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravesical
Antibiotics, Antineoplastic / administration & dosage,  metabolism*,  therapeutic use
Dose-Response Relationship, Drug
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Epirubicin / administration & dosage,  metabolism*,  therapeutic use
Fluorescence
Humans
Tumor Cells, Cultured
Urinary Bladder Neoplasms / drug therapy,  metabolism*
Verapamil / administration & dosage,  pharmacology
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 52-53-9/Verapamil; 56420-45-2/Epirubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The value of multiple free-flow studies in men with lower urinary tract symptoms.
Next Document:  Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging...